Lantheus moves forward with study of 18F-flurpiridaz for MPI

05/1/2013 | AuntMinnie.com (free registration)

Lantheus Medical Imaging said the first Phase III trial involving its 18F-flurpiridaz PET agent has cleared a data analysis milestone, and the research will continue. The program comprises two trials involving 1,400 North American and European patients. The agent is being tested in myocardial perfusion imaging of patients believed or known to have coronary artery disease.

View Full Article in:

AuntMinnie.com (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC